Dr. Pawlotsky is or has been a consultant for Hoffmann-La Roche, Schering Plough Oncology, Isis Pharmaceuticals, Abbott Diagnostics, Ortho-Diagnostics, AcroMetrix, Inc, and Chiron-Blood Testing. He has received research grants from Hoffmann-La Roche and Schering Plough Oncology.
Use and interpretation of virological tests for hepatitis C
Article first published online: 30 DEC 2003
Copyright © 2002 American Association for the Study of Liver Diseases
Supplement: Management of Hepatitis C: 2002
Volume 36, Issue Supplement 5B, pages s65–s73, November 2002
How to Cite
Pawlotsky, J.-M. (2002), Use and interpretation of virological tests for hepatitis C. Hepatology, 36: s65–s73. doi: 10.1053/jhep.2002.36815
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- French Ministry for Research, the “Agence Nationale de Recherches sur le SIDA et l'Hépatite C” (ANRS)
- “Réseau National Hépatites,”
- “Ligue Française contre le Cancer.”
Four virological markers of hepatitis C virus (HCV) infection are used clinically for management of patients with hepatitis C, namely the HCV genotype, HCV RNA, HCV core antigen, and antibody to HCV (anti-HCV). The diagnosis of acute and chronic hepatitis C is based on both anti-HCV detection using enzyme immunoassays (EIA) and HCV RNA detection using a sensitive molecular biology-based technique. Other virological tools, including HCV genotype determination and HCV RNA quantification, are now used to tailor treatment to the individual patient and to determine its efficacy. This article reviews the kinetics of HCV markers during acute and chronic HCV infection, together with current assays and their practical use in the management of HCV-infected patients.